Highlights

  • Third quarter net loss was USD 26,612 thousand against USD 27,548 thousand.
  • The board approved a restructuring on October 2, 2026 and a strategic alternatives process.
  • Cash and cash equivalents were USD 26,057 thousand at September 30, 2026.
  • Net cash provided by financing for nine months was USD 23,621 thousand.

Caribou Biosciences, Inc. (NASDAQ:CRBU) shares were trading near their all-time low at USD 0.4202 on November 6, 2026, up 1.92% on the day. The company reported a third quarter net loss of USD 26,612 thousand, or USD 0.25 per share.

Restructuring and Strategic Alternatives

On October 6, 2026, the company announced that its board approved a restructuring on October 2, 2026 while it conducts a process to explore strategic alternatives to maximize stockholder value. The restructuring includes the planned discontinuation of Clinical Trials and further development of two allogeneic CAR-T cell therapy programs, vispacabtagene regedleucel (vispa-cel) and CB-011.

It also includes a substantial reduction of the workforce and other cost reduction measures.

Third Quarter Results

Total operating expenses were USD 29,249 thousand against USD 31,598 thousand. The loss from operations was USD 27,642 thousand against USD 29,400 thousand. The net loss was USD 26,612 thousand against USD 27,548 thousand, and the loss per share was USD 0.25 against USD 0.30.

For the nine months ended September 30, 2026, total operating expenses were USD 84,764 thousand against USD 127,109 thousand. The net loss was USD 75,979 thousand, or USD 0.75 per share, against USD 121,637 thousand, or USD 1.31 per share.

Cash and Balance Sheet

Cash and cash equivalents were USD 26,057 thousand at September 30, 2026 against USD 12,360 thousand at December 31, 2025. Total Assets were USD 123,026 thousand against USD 175,367 thousand.

Total liabilities were USD 46,393 thousand against USD 53,192 thousand, and total stockholders' Equity was USD 76,633 thousand against USD 122,175 thousand. The accumulated Deficit was USD 672,494 thousand.

Cash Flow

Net cash used in Operating Activities was USD 72,289 thousand for the nine months against USD 90,168 thousand. Net cash provided by financing activities was USD 23,621 thousand against USD 751 thousand.

The filing states that the company has incurred operating losses and negative cash flows since inception and used cash in operations during the nine months. It had 108,036,729 shares outstanding as of November 2, 2026.